AM109 / AbClon - LARVOL DELTA

AM109, a PSMA×CD137 bispecific antibody with target-dependent T cell activation and potent anti-tumor activity in prostate cancer (AACR 2026) - "In vivo efficacy was evaluated using human CD137 transgenic mice bearing hPSMA/MC38 tumors, where AM109 achieved complete tumor regression at doses of 0.1-0.3 mpk, exhibiting superior potency compared with the reference CD137 agonist utomilumab. Collectively, these findings demonstrate that AM109 selectively activates T cells within the tumor microenvironment, eliciting potent and PSMA-dependent anti-tumor responses with an improved therapeutic window. AM109 therefore represents a promising next-generation immunotherapeutic candidate for the treatment of mCRPC."

Bispecific • IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD8 • FOLH1 • GZMB • IFNG • TNFRSF9